The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relevance of timing intake of everolimus (EVE) combined with adjuvant endocrine therapy (ET) in patients (pts) with high-risk early breast cancer: Results of a sub-study of the UCBG-UNIRAD trial.
 
Enora Laas
No Relationships to Disclose
 
Anne-Sophie Hamy
No Relationships to Disclose
 
Thomas Bachelot
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Pfizer (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; pfizer; Roche
 
Jerome Lemonnier
No Relationships to Disclose
 
Fabrice Andre
Consulting or Advisory Role - AstraZeneca (Inst); Boston Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Lilly; Lilly (Inst); N-Power Medicine (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); ROCHE (Inst); SERVIER (Inst)
Research Funding - AstraZeneca (Inst); Daiichi (Inst); Guardant Health (Inst); Lilly (Inst); Novartis (Inst); Owkin (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Novartis; Roche
 
David A. Cameron
Consulting or Advisory Role - AstraZeneca (Inst); Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); ERYTECH Pharma (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); Grail (Inst); Lilly (Inst); Next Generation Healthcare communications (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Judith Bliss
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); GlaxoSmithKline/Novartis (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Sylvie Chabaud
No Relationships to Disclose
 
Anne-Claire Hardy-Bessard
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; MSD; Novartis; Pfizer; Seagen
 
Magali Lacroix-Triki
Honoraria - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Genomic Health; MSD Oncology; Myriad Genetics; Roche Diagnostics Solutions
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Roche Diagnostics Solutions
 
Marc Debled
No Relationships to Disclose
 
Mario Campone
Honoraria - Lilly; Novartis
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Daiichi Sankyo Europe GmbH; Diaccurate (Inst); Lilly (Inst); Menarini; Novartis (Inst); PET-THERAPY (Inst); Pfizer; Pierre Fabre (Inst); Sandoz-Novartis (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - Amgen; Lilly (Inst); Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
Other Relationship - Roche
 
Paul H. Cottu
Honoraria - AstraZeneca; Daiich Sankyo; Gilead Sciences; Gilead Sciences; Gilead Sciences; Lilly; NanoString Technologies (Inst); Novartis (Inst); Pfizer; Roche
Consulting or Advisory Role - Lilly; Pfizer
Research Funding - pfizer (Inst)
Travel, Accommodations, Expenses - Lilly; pfizer; Roche
 
Florence Dalenc
Honoraria - AstraZeneca; Gilead Sciences (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo (Inst); Gilead Sciences; Novartis (Inst); Pfizer (Inst)
 
Olivier Tredan
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Eisai Europe; Gilead Sciences; Lilly; MSD Oncology; Pfizer; Pierre Fabre; Roche; Sandoz-Novartis; Stemline Therapeutics; Veracyte
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; MSD Oncology; Novartis; Pfizer; Roche
 
Frederique Madeleine Penault-Llorca
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); AstraZeneca/Daiichi Sankyo; BAYER; BeiGene; BMS; Eisai Europe; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Illumina; Janssen; Lilly; Lilly (Inst); MSD; MSD/AstraZeneca; Myriad genetics; NanoString Technologies; Novartis; Pfizer; Roche; Roche (Inst); SERVIER
Research Funding - Bayer (Inst); MSD (Inst); Myriad Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer (Inst); Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Lilly; MSD (Inst); Novartis; Pfizer; Roche (Inst)
 
Bernard Asselain
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Roche
 
Fabien Reyal
No Relationships to Disclose
 
Francis Levi
Research Funding - Philips Respironics (Inst)
Patents, Royalties, Other Intellectual Property - INSERM patent on I (Inst)
Other Relationship - ETIC Systems
 
Sylvie Giacchetti
Consulting or Advisory Role - AstraZeneca; Eisai; Exact Sciences; Lilly; Novartis
Research Funding - AstraZeneca (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Daichi sankyo; Lilly; Merck; Novartis; Viatris